Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
13.00    0.50 (4.00%)
Bid:
12.50
Ask:
13.50
Spread: 1.00 (8.00%)
Market Cap: £16.25m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

25 Jun 2007 11:36

Fabian Romania Property Fund Ltd25 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or "Fabian") Fabian Romania acquires a 50 per cent. interest in a residential developmentsite to build 250 apartments in Timisoara for €4.7 million Fabian Romania is pleased to announce that it has purchased 50 per cent. of adevelopment company owning a 1.1 hectare site in north Timisoara. The equityconsideration amounts to approximately €1 million. The land area totals approximately 11,000 square metres and has urban zoningapproval to build over 250 apartments (subject to building permits) comprisingover 30,000 square metres of residential development space. Coltex, theco-shareholder holding the other 50% interest, has entered into a partnershipagreement with Fabian. Coltex will also be the development manager and has aknown track record, having developed and sold the successful Banu Antonachebuilding to Fabian in late 2005. Timisoara is Romania's third largest city with a population of over 300,000 andis located in the West close to the Hungarian border. The Investment Managerbelieves the city has attractive characteristics for supply of modernresidential apartments. The purchase price for the land including acquisition expenses was €4.7 million.This equates to around €427 per square metre for the land and €157 per builtsquare metre overground, assuming 30,000 square metres. The development companyhas already secured and fully drawdown on a land finance facility from BancaRomaneasca for €3.6 million. Including near term working capital needs, thisleaves an initial net equity requirement of approximately €1 million for Fabian. Responsible for the acquisition, Mark Owen, Property Director of Fabian Capital,Fabian Romania's investment adviser said: "This is the first investment for Fabian outside Bucharest and our secondresidential scheme. The purchase price for the land is extremely attractiverelative to comparable plots in Bucharest. We are also happy to have enteredinto a new partnership with Coltex for this development. Whilst it is clearTimisoara is in its infancy within the development process, strong indicationsexist that the residential sector is very undersupplied and that demand existsfor good, mid market apartments against a background of increasing prices." For Comments: Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.